See also this year's filing and all EDGAR filings for this company.
PDF Report 0001426332_2023_NGM_BIOPHARMACEUTICALS_INC.pdf
Logs
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'PROVECTUS BIOPHARMACEUTICALS INC.', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'REGENERX BIOPHARMACEUTICALS INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001426332, NGM BIOPHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 288,859,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 8,496,000 |
| 3 | remainder_Assets | 10,047,000 |
| 4 | LiabilitiesCurrent | 47,842,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 40,515,000 |
| 9 | ResearchAndDevelopmentExpense | 181,067,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 55,333,000 |
| 12 | remainder_NetIncome | 3,582,000 |
| 13 | remainder_ComprehensiveNetIncome | -173,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 307,402,000 |
| 1 | Liabilities | 47,842,000 |
| 2 | Expenses | 221,582,000 |
| 3 | Revenues | 55,333,000 |
| 4 | StockholdersEquity | 259,560,000 |
| 5 | NetIncome | -162,667,000 |
| 6 | ComprehensiveNetIncome | -162,753,500 |
| 7 | BaseVar | 317,957,000 |
| 8 | EconomicCapitalRatio | 1.60 |
Edgar->Model Mapping
Feature Distribution
Change over Time
